NuCana (NASDAQ:NCNA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of NuCana (NASDAQ:NCNA) from a sell rating to a hold rating in a research report report published on Saturday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of NuCana in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company currently has an average rating of “Sell”.

NuCana Stock Up 8.6%

Shares of NCNA opened at $3.80 on Friday. NuCana has a twelve month low of $2.78 and a twelve month high of $330.00. The company has a market capitalization of $114,000.00, a P/E ratio of -0.02 and a beta of 1.51. The firm has a 50 day moving average of $4.29 and a 200 day moving average of $8.85.

NuCana (NASDAQ:NCNA) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.69) by $2.59. On average, sell-side analysts expect that NuCana will post -13.42 EPS for the current year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.